Claims
- 1. A compound of the formula ##STR32## in which R.sup.1 and R.sup.2 are hydrogen, or R.sup.1 and R.sup.2 together form a chain of the formula ##STR33## wherein R.sup.6, R.sup.7, R.sup.8 and R.sup.9 each is hydrogen or lower alkoxy; R.sup.3 is selected from the group consisting of ##STR34## wherein R.sup.10 is hydrogen, halo, lower alkyl, lower alkoxy, hydroxy, 1-oxo(lower)alkoxy or NR.sup.11 R.sup.12 wherein R.sup.11 and R.sup.12 each is hydrogen or lower alkyl; A is NR.sup.13 wherein R.sup.13 is lower alkyl; R.sup.4 and R.sup.5 each is hydrogen or lower alkyl; and n is 1 or 2; or a therapeutically acceptable acid addition salt thereof.
- 2. A compound of claim 1 of the formula ##STR35## in which R.sup.4, R.sup.5 and R.sup.6 are hydrogen, R.sup.7 and R.sup.8 each is lower alkoxy, R.sup.9 is hydrogen or lower alkoxy, R.sup.3 is selected from the group consisting of ##STR36## wherein a is NR.sup.13 wherein R.sup.13 is lower alkyl; R.sup.10 is hydrogen, halo or lower alkoxy; and n is 1; or a therapeutically acceptable acid addition salt thereof.
- 3. A compound of claim 1 of the formula ##STR37## in which R.sup.4, R.sup.5 and R.sup.6 are hydrogen, R.sup.7 and R.sup.8 each is lower alkoxy, R.sup.9 is hydrogen or lower alkoxy, R.sup.3 is selected from the group consisting of ##STR38## wherein A is NR.sup.13 wherein R.sup.13 is lower alkyl; and n is 1; or a therapeutically acceptable acid addition salt thereof.
- 4. 6,7-Dimethoxy-2-[4-(1-methyl-2-benzimidazolyl)-1-piperazinyl]-4-quinazolinamine, as claimed in claim 1.
- 5. 6,7-Dimethoxy-2-[4-[1-(1-methylethyl)-1H-benzimidazol-2-yl]-1-piperazinyl]-4-quinazolinamine, as claimed in claim 1.
- 6. 6,7-Dimethoxy-2-[4-(1-propyl-1H-benzimidazol-2-yl)-1-piperazinyl]-4-quinazolinamine, as claimed in claim 1.
- 7. 6,7-Dimethoxy-2-[4-(2-thiazolyl)-1-piperazinyl]-4-quinazolinamine, as claimed in claim 1.
- 8. 6,7-Dimethoxy-2-[4-(oxazolo[4,5-b]pyridin-2-yl)-1-piperazinyl]-4-quinazolinamine, as claimed in claim 1.
- 9. A pharmaceutical composition for treating hypertension, which comprises a compound of claim 1, and a pharmaceutically acceptable carrier therefor.
- 10. A method of treating hypertension in a hypertensive mammal, which comprises administering to said mammal an effective antihypertensive amount of a compound of claim 1.
- 11. A method of treating hypertension in a hypertensive mammal, which comprises administering to said mammal an antihypertensive effective amount of a compound of claim 1, in combination with an effective amount of a second therapeutic agent comprising a diuretic, an antihypertensive agent of a combination of a diuretic and an antihypertensive agent.
- 12. The method of claim 11 in which the second therapeutic agent is diuretic thiazide, a mineralocorticoid antagonizing diuretic agent or a .beta.-adrenergic blocking agent.
- 13. The method of claim 11 in which the second therapeutic agent is chlorothiazide, hydrochlorothiazide or propranolol.
- 14. The method of claim 11 in which the compound of formula I, and the second therapeutic agent are administered sequentially or simultaneously.
- 15. A pharmaceutical composition comprising a compound of claim 1, and a second therapeutic agent comprising a diuretic or antihypertensive agent.
- 16. The pharmaceutical composition of claim 15 in which the second therapeutic agent is a diuretic thiazide, a mineralocorticoid antagonizing diuretic agent or a .beta.-adrenergic blocking agent.
- 17. The pharmaceutical composition of claim 15 in which the agent is chlorothiazide, hydrochlorothiazide or propranolol.
Parent Case Info
This application is a continuation-in-part of Ser. No. 141,548, Apr. 18, 1980, U.S. Pat. No. 4,333,937.
US Referenced Citations (5)
Non-Patent Literature Citations (2)
Entry |
Al Thuis et al., J. Med. Chem., 20, 146-149, (1977). |
Derwent Publications Ltd., Farm Doc. 36461B for Netherland, Patent 7,804,135. |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
141548 |
Apr 1980 |
|